Division of Brain Sciences, Imperial College London, UK.
Department of Medicine and Health Sciences, School of Medicine, University of Molise, Campobasso, Italy.
Mov Disord. 2016 Mar;31(3):344-51. doi: 10.1002/mds.26456. Epub 2016 Feb 11.
Ten to fifteen percent of Parkinson's disease (PD) patients recruited to clinical trials have scans without evidence of dopaminergic deficit, whose presence represents a heterogeneous patient population.
A cohort of 41 patients with parkinsonism and scans without evidence of dopaminergic deficit at baseline, were subdivided into groups according to their final clinical diagnoses and nigrostriatal dopamine function assessed after 2 years of study. At follow up, 23 patients had clinically probable PD or unclassified parkinsonism with normal nigrostriatal dopamine imaging ("true" scans without evidence of dopaminergic deficit), nine were diagnosed with another tremulous condition, five had psychogenic parkinsonism, and four had phenoconverted to PD with reduced nigrostriatal dopamine function. We analyzed nonmotor symptoms at baseline and follow-up in subgroups of patients with scans without evidence of dopaminergic deficit in comparison with a random sample of 62 PD patients and 195 healthy controls (HCs). All patients were enrolled in the Parkinson's Progressive Marker's Initiative.
Patients who had true scans without evidence of dopaminergic deficit had more severe rapid eye movement sleep disorder, depression, anxiety, and autonomic dysfunction than HCs in addition to more frequent depressive symptoms and worse cardiovascular dysfunction than patients with PD (P = 0.038, P = 0.047, respectively). Patients with true scans without evidence of dopaminergic deficit had normal olfaction that was significantly better than that of patients with PD (P < 0.001). Subgroup analysis of the cohort with scans without evidence of dopaminergic deficit revealed that all patients shared similar nonmotor features irrespective of their final clinical diagnoses. Follow-up of subject groups showed stable nonmotor symptoms over 2 years of study.
At an early symptomatic stage, patients with scans without evidence of dopaminergic deficit and long-standing parkinsonism exhibit nonmotor features that differ from those of patients with PD on mood and cardiovascular and olfactory function, but remain similar to patients with scans without evidence of dopaminergic deficit with alternative final diagnoses.
在入组临床试验的帕金森病(PD)患者中,有 10%至 15%的患者扫描结果没有多巴胺能缺陷的证据,这些患者代表了一种异质性的患者群体。
本研究纳入了 41 例有帕金森症且基线时扫描结果无多巴胺能缺陷的患者。根据他们最终的临床诊断和 2 年后的研究评估黑质纹状体多巴胺功能,将这些患者分为不同的亚组。在随访时,23 例患者被诊断为临床可能的 PD 或未分类的帕金森症且黑质纹状体多巴胺成像正常(“真正的”无多巴胺能缺陷扫描),9 例被诊断为其他震颤性疾病,5 例为心因性帕金森症,4 例表现为 Phenoconverted 为 PD 且黑质纹状体多巴胺功能降低。我们分析了亚组患者的非运动症状,这些患者在基线和随访时扫描结果无多巴胺能缺陷,并与随机抽取的 62 例 PD 患者和 195 例健康对照组(HCs)进行比较。所有患者均被纳入帕金森进展标志物倡议。
与 HCs 相比,“真正的”无多巴胺能缺陷扫描患者的快速眼动睡眠障碍、抑郁、焦虑和自主神经功能障碍更为严重,且抑郁症状更为频繁,心血管功能障碍更为严重,而与 PD 患者相比,“真正的”无多巴胺能缺陷扫描患者的抑郁症状更为严重,心血管功能障碍更为严重(P = 0.038,P = 0.047)。“真正的”无多巴胺能缺陷扫描患者的嗅觉正常,明显优于 PD 患者(P < 0.001)。对无多巴胺能缺陷扫描亚组的分析表明,无论最终的临床诊断如何,所有患者的非运动特征相似。对亚组的随访显示,在 2 年的研究期间,非运动症状稳定。
在早期有症状阶段,无多巴胺能缺陷和长期帕金森症患者的非运动特征在情绪、心血管和嗅觉功能方面与 PD 患者不同,但与其他最终诊断为无多巴胺能缺陷的患者相似。